Viking Therapeutics, Inc. - VKTX STOCK NEWS

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focusing on novel therapies for metabolic and endocrine disorders, has announced its plans to release financial results for the second quarter of 2024 after market close on July 24, 2024. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide general corporate updates.

Interested parties can participate in the conference call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. A telephone replay will be available until July 31, 2024. The call can also be accessed via webcast on Viking's website, with an archive available for 30 days.

Viking Therapeutics (NASDAQ: VKTX) presented preclinical data on its novel dual amylin and calcitonin receptor agonists (DACRAs) at the 84th Scientific Sessions of the American Diabetes Association. The studies showcased significant reductions in body weight and food intake in healthy rats and diet-induced obese (DIO) mice, with improvements in key metabolic markers such as blood glucose levels.

Viking's DACRAs achieved up to 8% body weight reduction in lean rats 72 hours post a single dose, and up to 10% weight loss in DIO mice over 24 days. Additionally, a 24% reduction in blood glucose was observed in DIO mice after 24 days. The compounds demonstrated EC50 values ranging from low nM to micromolar on the human amylin 3 and calcitonin receptors. These results support the continued development of Viking's dual agonist program targeting obesity and metabolic diseases.

Viking Therapeutics has announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed NASH. VK2809 demonstrated significant efficacy across key endpoints: up to 75% of treated patients achieved NASH resolution with no worsening of fibrosis, and up to 57% showed a ≥1-stage improvement in fibrosis without worsening of NASH. The safety profile was consistent with earlier results, with most adverse events being mild or moderate. The results also showed substantial reductions in liver fat content and plasma lipids, indicating potential cardio-protective benefits.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, announced participation in two upcoming investor conferences.

At the 2024 Jefferies Global Healthcare Conference, Viking will deliver a corporate presentation and engage in 1-on-1 meetings on June 5-6, 2024, at the Marriott Marquis, New York. The presentation is scheduled for June 6, 2024, from 10:30 to 10:55 a.m. Eastern.

Viking will also participate in 1-on-1 meetings at the Stifel 2nd European Healthcare Summit from June 25-27, 2024, at the InterContinental Lyon Hotel Dieu, Lyon, France.

A live webcast of the Jefferies presentation will be available on Viking’s website, with a replay accessible following the conference.

Viking Therapeutics, a biopharmaceutical company, reported positive results from Phase 2 trials of VK2735 for obesity, showcasing up to 13.1% weight loss. The company also raised $630 million in a public offering, ending the quarter with $963 million in cash. The Phase 2b VOYAGE study evaluating VK2809 for NASH and fibrosis is progressing well, with histology results expected soon.

Viking Therapeutics, a clinical-stage biopharmaceutical company, will report its financial results for the first quarter of 2024 on April 24, 2024. The company will host a conference call to discuss the results and general corporate updates on the same day at 4:30 p.m. Eastern Time. Investors and analysts can participate in the call by dialing the provided numbers. A telephone replay will be available until May 1, 2024, and the conference call can also be accessed live via the internet.

Viking Therapeutics, Inc. announces positive Phase 1 trial results for VK2735, showing up to 3.3% placebo-adjusted mean weight loss and low GI-related adverse events. Phase 2 trial for obesity planned in 2H24.

Viking Therapeutics, Inc. announced the closing of a public offering, raising approximately $632.5 million. The offering included 7,441,650 shares of common stock at $85.00 per share, with additional shares purchased by underwriters. The proceeds will be used for the development of various programs and general corporate purposes.

Viking Therapeutics, Inc. announces the pricing of its underwritten public offering of 6,471,000 shares of common stock at $85.00 per share, aiming to raise approximately $550.0 million. The company granted underwriters an option to purchase additional shares, with all proceeds going to Viking.